Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.53 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.53 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.53 |
| ▸ | IDO1 | P14902 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.53 |
| ▸ | MITF | O75030 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11639364 | 0.84 | MEN1 (0.42) | KMT2AMEN1MAPTMAPK1POLB | |
| SCHEMBL5311132 | 0.83 | KMT2A (0.56) | KMT2AMEN1MAPTMAPK1POLB | |
| SCHEMBL1085867 | 0.82 | MEN1 (0.71) | KMT2AMEN1MAPTMAPK1POLB | |
| SCHEMBL8326648 | 0.82 | KMT2A (0.60) | KMT2AMEN1MAPTMAPK1POLB | |
| SCHEMBL10436614 | 0.80 | ALDH1A1 (0.53) | KMT2AMEN1MAPTMAPK1POLB | |
| SCHEMBL2371613 | 0.80 | KMT2A (0.50) | KMT2AMEN1MAPTMAPK1POLB | |
| SCHEMBL13852338 | 0.80 | KMT2A (0.50) | KMT2AMEN1MAPTMAPK1POLB | |
| SCHEMBL30543838 | 0.80 | KMT2A (0.63) | KMT2AMEN1MAPTMAPK1POLB | |
| SCHEMBL13302353 | 0.80 | MEN1 (0.69) | KMT2AMEN1MAPTMAPK1POLB | |
| SCHEMBL361514 | 0.80 | KMT2A (0.63) | KMT2AMEN1MAPTMAPK1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104507943-A | Substituted tricyclic compounds as FGFR inhibitors | INCYTE CORP | 2015-04-08 | — | — | CN | disclosed |
| US-8288549-B2 | Glycine B antagonist | MERZ PHARMA GMBH & CO. KGAA (DE) | 2012-10-16 | — | — | US | disclosed |
| US-20110190342-A1 | GLYCINE B ANTAGONIST | HENRICH MARKUS | 2011-08-04 | — | — | US | disclosed |
| EP-1831184-B1 | PYRAZINES AND PYRIDINES AND DERIVATIVES THEREOF AS THERAPEUTIC COMPOUNDS | WELLCOME TRUST LTD (GB) | 2011-02-09 | — | — | EP | disclosed |
| US-7737152-B2 | 6-carboaryl-oxy-pyrazin-2-yl-carboaryl-amines and compositions comprising said compounds | THE WELLCOME TRUST LIMITED (GB) | 2010-06-15 | — | — | US | disclosed |
| US-20080015191-A1 | Pyrazines and Pyridines and Derivatives Thereof as Therapeutic Compounds | THE WELLCOME TRUST LIMITED (UK) | 2008-01-17 | — | — | US | disclosed |
| EP-1831184-A2 | PYRAZINES AND PYRIDINES AND DERIVATIVES THEREOF AS THERAPEUTIC COMPOUNDS | The Wellcome Trust Limited (GB) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006067466-A2 | PYRAZINES AND PYRIDINES AND DERIVATIVES THEREOF AS THERAPEUTIC COMPOUNDS | THE WELLCOME TRUST LIMITED (GB) | 2006-06-29 | — | — | WO | disclosed |
| US-6229055-B1 | SYNTHESIS OF FLUORINATED RESORCINOL WHICH IS USEFUL IN THE PREPARATION OF FLUORINATED FLUORESCEIN AND RHODOL DYES SUITABLE FOR USE AS TRACERS, LABELS, OR INTERMEDIATES | MOLECULAR PROBES, INC. | 2001-05-08 | — | — | US | disclosed |
| US-6162931-A | Fluorinated xanthene derivatives | MOLECULAR PROBES, INC. (US) | 2000-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015191-A1 | Pyrazines and Pyridines and Derivatives Thereof as Therapeutic Compounds | BRAF, RAF1, BCOR | KMT2A 2377/4885MEN1 2600/4885MAPT 4774/4885 |
| US-20110190342-A1 | GLYCINE B ANTAGONIST | GRIN2B, GLRB, GRIN2A | KMT2A 1700/4885MEN1 808/4885MAPT 1267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.